Search

Your search keyword '"Fiebig, Frank"' showing total 8 results
Start Over Author "Fiebig, Frank"
8 results on '"Fiebig, Frank"'

1. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study

Author

Röllig, Christoph, primary, Schliemann, Christoph, additional, Ruhnke, Leo, additional, Fransecky, Lars, additional, Heydrich, Björn‐Niklas, additional, Hanoun, Maher, additional, Noppeney, Richard, additional, Schäfer‐Eckart, Kerstin, additional, Wendelin, Knut, additional, Mikesch, Jan‐Henrik, additional, Middeke, Jan Moritz, additional, Reimann, Manja, additional, Fiebig, Frank, additional, Zukunft, Sven, additional, Wermke, Martin, additional, Serve, Hubert, additional, Platzbecker, Uwe, additional, Müller‐Tidow, Carsten, additional, Baldus, Claudia D., additional, and Bornhäuser, Martin, additional

Published
2024
Full Text
View/download PDF

2. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)

Author

Sockel, Katja, primary, Mütherig, Anke, additional, Crysandt, Martina, additional, Hänel, Mathias, additional, Noppeney, Richard, additional, Schaefer-Eckart, Kerstin, additional, Kaufmann, Martin, additional, Röllig, Christoph, additional, Schetelig, Johannes, additional, Zukunft, Sven, additional, Fiebig, Frank, additional, Giagounidis, Aristoteles, additional, Scholl, Sebastian, additional, Lück, Andreas, additional, Rieger, Kathrin, additional, Götze, Katharina, additional, Geer, Thomas, additional, Kiewe, Philipp, additional, Müller-Tidow, Carsten, additional, Serve, Hubert, additional, Baldus, Claudia, additional, Kaiser, Ulrich, additional, Mahlmann, Stefan, additional, Schmidt, Burkhard, additional, Parmentier, Stefani, additional, Illmer, Thomas, additional, Seggewiß-Bernhardt, Ruth, additional, Kiani, Alexander, additional, Linde, Hartmut, additional, Dürk, Heinz, additional, Kramer, Michael, additional, Kunadt, Desiree, additional, Schmidt-Brücken, Katharina, additional, Hase, Jana, additional, Helas, Susann, additional, Moritz Middeke, Jan, additional, von Bonin, Malte, additional, Oelschlaegel, Uta, additional, Ehninger, Gerhard, additional, Thiede, Christian, additional, Bornhauser, Martin, additional, and Platzbecker, Uwe, additional

Published
2023
Full Text
View/download PDF

3. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Author

Röllig, Christoph, primary, Steffen, Björn, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Alakel, Nael, additional, Herbst, Regina, additional, Haenel, Mathias, additional, Noppeney, Richard, additional, Hanoun, Maher, additional, Kaufmann, Martin, additional, Racil, Zdenek, additional, Schäfer-Eckart, Kerstin, additional, Sauer, Tim, additional, Neubauer, Andreas, additional, Baldus, Claudia D., additional, Mertova, Jolana, additional, Jost, Edgar, additional, Niemann, Dirk, additional, Novak, Jan, additional, Krause, Stefan W., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Held, Gerhard, additional, Szotkowski, Tomáš, additional, Schmid, Christoph, additional, Rank, Andreas, additional, Fransecky, Lars, additional, Kramer, Michael, additional, Fiebig, Frank, additional, Haake, Annett, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Middeke, Jan Moritz, additional, Platzbecker, Uwe, additional, Thiede, Christian, additional, Müller-Tidow, Carsten, additional, Berdel, Wolfgang E., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Mayer, Jiří, additional, and Bornhaeuser, Martin, additional

Published
2022
Full Text
View/download PDF

4. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Author

Röllig, Christoph, primary, Fransecky, Lars, additional, Hanoun, Maher, additional, Steffen, Björn, additional, Kraus, Sabrina, additional, Schliemann, Christoph, additional, Haake, Annett, additional, Fiebig, Frank, additional, Zukunft, Sven, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Bornhaeuser, Martin, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Ruhnke, Leo, additional, Kramer, Michael, additional, Von Bonin, Malte, additional, Röhnert, Maximilian Alexander, additional, Oelschlägel, Uta, additional, Baldus, Claudia D., additional, Serve, Hubert, additional, and Wermke, Martin, additional

Published
2022
Full Text
View/download PDF

5. Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Author

Röllig, Christoph, primary, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Fransecky, Lars, additional, Baldus, Claudia D., additional, Heydrich, Björn-Niklas, additional, Hanoun, Maher, additional, Noppeney, Richard, additional, Scholl, Sebastian, additional, Schnetzke, Ulf, additional, Schäfer-Eckart, Kerstin, additional, Wendelin, Knut, additional, Wermke, Martin, additional, Reimann, Manja, additional, Fiebig, Frank, additional, Kretschmann, Theresa, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, and Bornhäuser, Martin, additional

Published
2021
Full Text
View/download PDF

6. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Author

Röllig, Christoph, Steffen, Björn, Alakel, Nael, Herbst, Regina, Noppeney, Richard, Hanoun, Maher, Racil, Zdenek, Schäfer-Eckart, Kerstin, Krämer, Alwin, Neubauer, Andreas, Baldus, Claudia D, Schliemann, Christoph, Kaufmann, Martin, Mertova, Jolana, Jost, Edgar, Niemann, Dirk, Novak, Jan, Krause, Stefan W, Scholl, Sebastian, Held, Gerhard, Parmentier, Stefani B., Szotkowski, Tomáš, Zak, Pavel, Rank, Andreas, Wass, Maxi, Buske, Sebastian, Kramer, Michael, Fiebig, Frank, Haake, Annett, Schetelig, Johannes, Platzbecker, Uwe, Thiede, Christian, Müller-Tidow, Carsten, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Mayer, Jiri, and Bornhäuser, Martin

Published
2020
Full Text
View/download PDF

7. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Author

Ruhnke, Leo, Schliemann, Christoph, Mikesch, Jan-Henrik, Stelljes, Matthias, Fransecky, Lars, Steffen, Björn, Kaufmann, Martin, Burchert, Andreas, Rank, Andreas, Hanoun, Maher, Höllein, Alexander, Kraus, Sabrina, Hänel, Mathias, Schäfer-Eckart, Kerstin, Haake, Annett, Fiebig, Frank, Zukunft, Sven, Middeke, Jan Moritz, Kunadt, Désirée, Schetelig, Johannes, von Bonin, Malte, Röhnert, Maximilian Alexander, Oelschlägel, Uta, Stölzel, Friedrich, Baldus, Claudia D, Serve, Hubert, Wermke, Martin, Bornhäuser, Martin, and Röllig, Christoph

Abstract

Background

Published
2023
Full Text
View/download PDF

8. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Author

Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, and Bornhäuser M

Abstract

Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m 2 with 90 mg/m 2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction., Patients and Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m 2 daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle., Results: Eight hundred and sixty-four patients with a median age of 52 years were randomly assigned. After a preplanned interim analysis showing no significant difference in response between 60 and 90 mg/m 2 , all consecutive patients received 60 mg/m 2 daunorubicin once daily. The proportion of good early responders was 44% versus 48% ( P = .983) with a composite complete remission (CRc) rate of 90% versus 89% after induction ( P = .691); the 3-year relapse-free survival (RFS) after 60 versus 90 mg/m 2 once daily was 54% versus 50% ( P = .561), and the 3-year overall survival (OS) was 65% versus 58% ( P = .242). Among 389 good responders, CRc rates at the end of induction were 87% after single induction and 85% after double induction. The 3-year RFS was 51% versus 60% (hazard ratio [HR], 1.3; P = .091), and the 3-year OS was 76% versus 75% after single versus double induction (HR, 1.0; P = .937)., Conclusion: The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m 2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results